ReportWire

Tag: outbreaks

  • Raw Oysters Behind Salmonella Outbreak Sweeping Across the US, CDC Warns

    If you’re looking to start 2026 on the right foot, it might be wise to avoid raw oysters for the time being. Health officials have linked an ongoing Salmonella outbreak to the popular seafood item.

    According to the Centers for Disease Control and Prevention, at least 64 people across 22 states have been sickened by the same outbreak strain of bacteria, and nearly two dozen have been hospitalized. While a common source of transmission hasn’t yet been identified, the majority of interviewed individuals reported eating raw oysters shortly before their illness began.

    “Epidemiologic data show that oysters may be contaminated with Salmonella and may be making people sick in this outbreak,” the CDC stated in its update released last week.

    Worse than it seems

    There are several different types of Salmonella bacteria that can cause illness in people, though the symptoms tend to be similar and gastrointestinal in nature. These include diarrhea, fever, and stomach cramps. The illness will usually clear up within a few days and without the need for antibiotic treatment. But in rare cases, the bacteria can spread to other parts of the body and cause life-threatening complications like meningitis or sepsis.

    A strain of Salmonella Telelkebir is behind the current outbreak. The first known cases date back to June 2025, while the latest were reported in November 2025. Twenty people have been hospitalized to date, though none have died.

    It can take up to a week for symptoms to start after exposure and three to four weeks before a case is identified as part of the same outbreak, so the actual toll is probably substantially worse than documented.

    “The true number of sick people in this outbreak is likely much higher than the number reported, and the outbreak may not be limited to the states with known illnesses,” the CDC said. “This is because many people recover without medical care and are not tested for Salmonella.”

    State and local health officials have been interviewing sickened people about their recent diet, and raw oysters have come up as a likely culprit for the outbreak. Out of 27 cases interviewed so far, three-quarters reported eating raw oysters in the week before they became sick.

    The one silver lining is that the outbreak strain of Salmonella doesn’t appear to be drug-resistant, meaning conventional antibiotics should work to help prevent or treat severe infections.

    What to do

    The CDC notes that raw oysters can be a potential contamination threat at any time of the year. And Salmonella isn’t the only germ that likes to call oysters home; the food can also carry foodborne infections like hepatitis A, Vibrio bacteria, and norovirus.

    As a result, health officials generally recommend avoiding raw oysters and clams altogether—a tip that’s all the more useful now, given this current outbreak.

    “Cook oysters before eating to reduce your risk of food poisoning,” the CDC stated.

    Ed Cara

    Source link

  • Canada Will Soon Lose Its Hard-Won Measles-Free Status. America Is Next

    A highly contagious disease once vanquished by vaccination is now on the brink of officially returning to North America. Canada is expected to lose its measles elimination status, and the U.S. might possibly soon follow.

    This week, Canada reported new cases of measles tied to an ongoing outbreak—one that began 12 months ago. The year of continuous transmission means that Canada will almost certainly lose its measles-free designation, experts say. And though the largest outbreaks of measles in the U.S. this year have officially ended, the country could potentially still lose its status in 2026, too.

    “As of today, it seems very, very likely that Canada will lose its measles elimination status, while the United States is also at substantial risk in the next 3 months,” Sten Vermund, chief medical officer at the Global Virus Network, a coalition of medical virologists focused on viral threats, told Gizmodo.

    A resurgent enemy

    Despite a highly effective vaccine for it, measles remains a serious public health threat across much of the globe. In 2023, it’s estimated to have sickened roughly 10 million people and killed over 100,000 worldwide, with most deaths occurring in unvaccinated children under five.

    Some countries, through widespread vaccination programs, have kept measles largely at bay by stopping its local transmission. The U.S. officially eliminated endemic measles in 2000, while the Americas as a whole first achieved elimination in 2016. Canada earned its measles-free status in 1998.

    But so long as measles is endemic somewhere, the disease can hitch a ride on infected travelers and threaten to regain a foothold in locally eliminated countries, especially when vaccination rates start to decline. It’s a threat that’s now hitting close to home in the U.S.

    Canada’s latest outbreak first began in October 2024 in the province of New Brunswick. Since then, the country has reported over 5,000 cases, nearly all of which are linked to the initial New Brunswick cluster. And though the flow of cases has significantly slowed down over time, it hasn’t stopped. On Monday, Canadian health officials reported 19 new cases during the week of October 18 (the most current data) and 136 recent cases across five jurisdictions.

    The World Health Organization regularly evaluates whether countries can be deemed locally free of measles. Travel-related outbreaks can and do still occur in these countries, but it takes more than a year of ongoing transmission for the WHO to even consider revoking a country’s measles-free card. The Pan American Health Organization (PAHO), a subset of the WHO, will meet next month for its annual assessment of the region’s status. And given the current situation, Canada will probably lose its measles-free mantle.

    What about the U.S.?

    The immediate outlook is a bit less grim for the U.S., though still far from great.

    Earlier this January, a large outbreak of measles began in Western Texas. More than 700 cases were ultimately documented before officials formally declared the outbreak over in mid-August. Another large outbreak occurred around the same time nearby in New Mexico, which saw roughly 100 cases before it appeared to die down in late September.

    The trouble is, there have been many other measles clusters happening across the U.S. this year, and some are ongoing. All told, there have been roughly 1,650 cases reported—the largest tally seen since 1992—and dozens of outbreaks reported nationwide in 2025. At least three people died of measles in the U.S. this year as well, the first deaths recorded in a decade. There are current outbreaks in South Carolina, Illinois, Minnesota, Arizona, and Utah, with the latter two states sharing a cluster that’s now over 120 cases and counting.

    Though the outbreak in Texas is over, it remains possible that health officials will link some of the current cases to it. This can occur if people in these states are found to be infected with the same or closely related strain of measles that sickened residents in Texas. If so, and if these cases last until January, the PAHO could very well decide to revoke the measles-free status of the U.S. early next year, too.

    But even if this scenario doesn’t happen, experts are still worried about measles becoming endemic in America soon enough, given the sheer amount of transmission we’ve seen this year.

    “I expect the US will lose its measles elimination status next year, as the U.S. in 2025 has already experienced almost 4 cases per 10 million, 87% of cases were related to an outbreak, i.e., not imported, and there have already been 43 outbreaks in less than one year,” Jessica Justman, an infectious disease specialist and epidemiologist at Columbia University’s Mailman School of Public Health, told Gizmodo.

    The country’s federal public health system isn’t exactly in steady hands either. Earlier this year, President Donald Trump appointed Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services, a man with a long history of misleading the public about the safety of vaccines, including the combined measles, mumps, and rubella (MMR) vaccine. And during the height of the Texas outbreak, both he and his allies downplayed its impact and touted unsupported treatments for the viral disease.

    How to stop the return of measles

    Formidable as measles is, we’ve long known how to best curtail its danger: vaccination.

    It might be too late to stop the official return of measles in Canada or even the U.S. But that doesn’t mean that all hope is lost. Notably, Canada wouldn’t even be the first country in the Americas to have lost this status in the last few years, as both Brazil and Venezuela did recently. However, these countries have since regained their designation.

    Though America certainly has a growing anti-vaccination problem, measles vaccination rates in the U.S. and Canada remain generally high (for now). The current outbreaks have occurred in regions where rates are much lower than average, such as Mennonite communities in Canada. In at least some of these communities, officials have said, residents aren’t necessarily opposed to vaccination but simply have less regular contact with doctors. And unlike the U.S., there are no major public health figureheads in Canada with a track record of anti-vaccination sentiment.

    All of which is to say that a dedicated public health response can still convince people to get their measles shots. And Vermund expects that Canadian health officials will lay out a detailed plan to the PAHO to get things back on course.

    According to Vermund, this plan should ideally include, among other things, stronger vaccination campaigns that target under-vaccinated regions like Alberta and Ontario; mobile clinics and school-based immunization drives; community engagement and public education to counter vaccine misinformation; and improved surveillance.

    That same framework should also work to boost flagging vaccination rates in the U.S., too. But under the reign of RFK Jr., the Centers for Disease Control and Prevention has been turned into a shadow of its former self, and the ongoing shutdown of the federal government might further hamper any assistance that the CDC can provide to local and state agencies.

    “A course correction for the U.S. will require an intensive vaccination campaign and funding to support the public health surveillance systems across all 50 states,” Justman said. “Neither of these seems likely in the current context.”

    Though Canada will lose its status first, measles might have an easier time getting reestablished in its downstairs neighbor. If so, plenty more children and their families will suffer as a result.

    Ed Cara

    Source link

  • The Return of Measles

    The Return of Measles

    Measles seems poised to make a comeback in America. Two adults and two children staying at a migrant shelter in Chicago have gotten sick with the disease. A sick kid in Sacramento, California, may have exposed hundreds of people to the virus at the hospital. Three other people were diagnosed in Michigan, along with seven from the same elementary school in Florida. As of Thursday, 17 states have reported cases to the CDC since the start of the year. (For comparison, that total was 19, plus the District of Columbia, for all of 2023, and just 6 for 2022.) “We’ve got this pile of firewood,” Matthew Ferrari, the director of the Center for Infectious Disease Dynamics at Penn State, told me, “and the more outbreaks that keep happening, the more matches we’re throwing at it.”

    Who’s holding the matchbook? There’s an easy answer to who’s at fault. One of the nation’s political parties, and not the other, turned against vaccines to some extent during the pandemic, leading to voter disparities in death rates. One party, and not the other, has a presumptive presidential candidate who threatens to punish any school that infringes on parental rights by requiring immunizations. And one party, but not the other, appointed a vaccine-skeptical surgeon general in Florida who recently sidestepped standard public-health advice in the middle of an outbreak. The message from Republicans, as The Washington Post’s Alexandra Petri joked in a recent column, can sound like this: “We want measles in the schools and books out of them!”

    But the politics of vaccination, however grotesque it may be in 2024, obscures what’s really going on. It’s true that vaccine attitudes have become more polarized. Conservative parents in particular may be opting out of school vaccine requirements in higher numbers than they were before. In the blood-red state of Idaho, for example, more than 12 percent of kindergartners received exemptions from the rules for the 2022–23 school year, a staggering rate of refusal that is up by half from where it was just a few years ago. Politicized recalcitrance is unfortunate, to say the least, and it can be deadly. Even so, America’s political divides are simply not the cause of any recent measles outbreak. The virus has returned amid a swirl of global health inequities. Any foothold that it finds in the U.S. will be where hyperlocal social norms, not culture-war debates, are causing gaps in vaccine access and acceptance. The more this fact is overlooked, the more we’re all at risk.

    Consider where the latest measles cases have been sprouting up: By and large, the recent outbreaks have been a blue-state phenomenon. (Idaho has so far been untouched; the same is true for Utah, with the nation’s third-highest school-vaccine-exemption rate.) Zoom into the county level, and you’ll find that the pattern is repeated: Measles isn’t picking on Republican communities; if anything, it seems to be avoiding them. The recent outbreak in Florida unfolded not in a conservative area such as Sarasota, where vaccination coverage has been lagging, but rather in Biden-friendly Broward County, at a school where 97 percent of the students have received at least one MMR shot. Similarly, the recent cases in Michigan turned up not in any of the state’s MAGA-voting, vaccine-forgoing areas but among the diverse and relatively left-wing populations in and around Ann Arbor and Detroit.

    Stepping back to look at the country as a whole, one can’t even find a strong connection—or, really, any consistent link at all—between U.S. measles outbreaks, year to year, and U.S. children’s vaccination rates. Sure, the past three years for which we have student-immunization data might seem to show a pattern: Starting in the fall of 2020, the average rate of MMR coverage for incoming kindergarteners did drop, if only by a little bit, from 93.9 to 93.1 percent; at the same time, the annual number of reported measles cases went up almost tenfold, from 13 to 121. But stretch that window back one more year, and the relationship appears to be reversed. In 2019, America was doing great in terms of measles vaccination—across the country, 95.2 percent of kindergartners were getting immunized, according to the CDC—and yet, in spite of this fantastic progress, measles cases were exploding. More than 1,200 Americans got sick with the disease that year, as measles took its greatest toll in a generation.

    It’s not that our high measles-vaccination coverage didn’t matter then or that our slightly lower coverage doesn’t matter now. Vaccination rates should be higher; this is always true. In the face of such a contagious disease, 95 percent would be good; 99 percent much better. When fewer people are protected, more people can get sick. In Matthew Ferrari’s terms, a dropping immunization rate means the piles of firewood are getting bigger. If and when the flames do ignite, they could end up reaching farther, and burning longer, than they would have just a year or two ago. In the midst of any outbreak large enough, where thousands are affected, children will die.

    Despite America’s fevered national conversation about vaccines, however, rates of uptake simply haven’t changed that much. Even with the recent divot in our national vaccine rates, the country remains in broad agreement on the value of immunity: 93 percent of America’s kindergartners are getting measles shots, a rate that has barely budged for decades. The sheer resilience of this norm should not be downplayed or ignored or, even worse, reimagined as a state of grace from which we’ve fallen. Our protection remains strong. In Florida, the surgeon general’s lackadaisical response to the crisis at the Broward County elementary school did not produce a single extra case of the disease, in spite of grim predictions to the contrary, almost certainly thanks to how many kids are already vaccinated.

    At the same time, however, measles has been thriving overseas. Its reemergence in America is not a function of the nation’s political divides, but of the disease’s global prevalence. Europe had almost 60,000 cases last year, up from about 900 in 2022. The World Health Organization reports that the number of reported cases around the world surged to 306,000, after having dropped to a record low of 123,000 in 2021. As the pandemic has made apparent, our world is connected via pathogens: Large outbreaks in other countries, where vaccination coverage may be low, have a tendency to seed tiny outbreaks in the U.S., where coverage has been pretty high, but narrow and persistent cracks in our defenses still remain. (In 2022, more than half of the world’s unvaccinated infants were concentrated in just 10 countries; some of these are measles hotspots at this moment.) This also helps explain why so many Americans got measles in 2019. That was a catastrophic year for measles around the world, with 873,000 reported cases in total, the most since 1994. We had pretty good protection then, but the virus was everywhere—and so, the virus was here.

    In high-income countries such as the U.S., Ferrari told me, “clustering of risk” tends to be the source of measles outbreaks more than minor changes in vaccine coverage overall. Even in 2019, when more than 95 percent of American kindergarteners were getting immunized, we still had pockets of exposure where protection happened to be weakest. By far the biggest outbreak from that year occurred among Hasidic Jewish populations in New York State. Measles was imported via Israel from the hot spot of Ukraine, and took off within a group whose vaccination rates were much, much lower than their neighbors’. In the end, more than 1,100 people were infected during that outbreak, which began in October 2018 and lasted for nearly a year. “A national vaccination rate has one kind of meaning, but all outbreaks are local outbreaks,” Noel Brewer, a professor at the University of North Carolina at Chapel Hill and a member of the federal Advisory Committee on Immunization Practices, told me. “They happen on a specific street in a specific group of houses, where a group of people live and interact with each other. And those rates of vaccination in that specific place can drop well below the rate of coverage that will forestall an outbreak.”

    We’ve seen this time and time again over the past decade. When bigger outbreaks do occur in the U.S., they tend to happen in tight-knit communities, where immunization norms are radically out of sync with those of the rest of American society, politics aside. In 2014, when an outbreak of nearly 400 cases took hold in Ohio, almost entirely within the Amish community, the local vaccination rate was estimated to be about 14 percent. (The statewide number for young children at that time was more than 95 percent.) In 2011 and 2017, measles broke out among the large Somali American community in Minnesota, where anti-vaccine messaging has been intense, and where immunization rates for 2-year-olds dropped from 92 percent 20 years ago to 35 percent in 2021. An outbreak from the end of 2022, affecting 85 people in and around Columbus, Ohio, may well be linked to the nation’s second-biggest community of Somalis.

    Care must be taken in how these outbreaks are discussed. In Minnesota, for example, state health officials have avoided calling out the Somali community, for fear of stigmatizing. But another sort of trouble may arise when Americans overlook exactly who’s at risk, and exactly why. Experts broadly agree that the most effective way to deal with local outbreaks is with local interventions. Brewer pointed out that during the 2019 outbreak in New York, for example, nurses who belonged to local Jewish congregations took on the role of vaccine advocates. In Minnesota, the Department of Health has brought on more Somali staff, who coordinate with local Somali radio and TV stations to share its message. Yet these efforts can be obscured by news coverage of the crisis that points to a growing anti-science movement and parents giving up on vaccination all across the land. When measles spread among New York’s orthodox Jews, The New York Times reported on “an anti-vaccine fervor on the left that is increasingly worrying health authorities.” When the virus hit Columbus, NBC News noted that it was “happening as resistance to school vaccination requirements is spreading across the country.”

    Two different public-health responses can be undertaken in concert, the experts told me: You treat the problem at its source, and you also take the chance to highlight broader trends. A spate of measles cases in one community becomes an opportunity for pushing vaccination everywhere. “That’s always an important thing for us to do,” Ferrari said. Even so, the impulse to nationalize the problem will have its own, infelicitous effects. First, it’s meaningfully misleading. By catastrophizing subtle shifts in vaccination rates, we frighten many parents for no reason. By insisting that every tiny outbreak is a product of our national politics, we distract attention from the smaller measures that can and should be taken—well ahead of any upsurge of disease—to address hyperlocal vaccination crises. And by exaggerating the scale of our divisions—by asserting that we’ve seen a dangerous shift on a massive scale, or an anti-vaccine takeover of the Republican Party—we may end up worsening the very problem that worries us the most.

    We are a highly vaccinated nation, our politics notwithstanding. Telling people otherwise only fosters more division; it feeds the feeling that taking or refusing measles shots is an important mode of self-expression. It further polarizes health behavior, which can only widen the cracks in our defenses. “We have become quite militant and moralistic about vaccination,” Brewer told me, “and we probably would do well to be less absolute.” Measles outbreaks overseas are growing; measles outbreaks here will follow. Their specific causes ought not be ignored.

    Daniel Engber

    Source link

  • WHO’s new COVID guidelines see fewer patients requiring hospitalization

    WHO’s new COVID guidelines see fewer patients requiring hospitalization

    Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.

    That’s according to the World Health Organization, which updated its COVID-19 guidelines on Friday for the 13th time.

    The guidelines highlight that fewer patients will require hospitalization as they are more likely to have non-severe COVID.

    “The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease,” the agency said in a statement.

    People who are immunosuppressed remain at higher risk, however, with an estimated hospitalization rate of 6%. But people who are older than 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.

    And patients who belong to neither of those groups are at low risk of hospitalization, at an estimated rate of just 0.5%. Most people are now considered low-risk, said the WHO.

    The agency continues to recommend the use of Paxlovid for anyone at high or moderate risk of hospitalization. The antiviral developed by Pfizer Inc.
    PFE,
    -1.20%

    is still the best choice for most eligible patients, given its therapeutic benefits, ease of use and fewer concerns about potential harms.

    In cases where Paxlovid is not available, the WHO recommends molnupiravir, an antiviral developed by Merck
    MRK,
    -1.11%
    ,
    or remdesivir, an antiviral developed by Gilead Sciences Inc.
    GILD,
    +0.92%

    Read now: Pfizer to more than double price of its COVID antiviral once drug moves to commercial market

    “For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol,” said the agency.

    The WHO said it recommends against the use of a new antiviral called VV116 for patients, apart from those who are enrolled in clinical trials.

    That oral antiviral is being developed by Junshi Biosciences and Vigonvita in China.

    It issued a warning against the use of ivermectin for people with non-severe COVID. The drug used to treat parasites in animals proved highly controversial during the pandemic when many people were persuaded by fraudulent research and online misinformation that it was an effective treatment.

    From the archive: ‘You will not believe what I’ve just found.’ Inside the ivermectin saga: a hacked password, mysterious websites and faulty data.

    Source link

  • Nobel Prize in medicine awarded to two scientists whose work enabled creation of mRNA vaccines against COVID-19

    Nobel Prize in medicine awarded to two scientists whose work enabled creation of mRNA vaccines against COVID-19

    STOCKHOLM (AP) — Two scientists won the Nobel Prize in medicine on Monday for discoveries that enabled the development of effective mRNA vaccines against COVID-19.

    The award was given to Katalin Karikó, a professor at Sagan’s University in Hungary and an adjunct professor at the University of Pennsylvania, and Drew Weissman, who performed his prizewinning research together with Karikó at the University of Pennsylvania.

    “Through their groundbreaking findings, which have fundamentally changed our understanding of how mRNA interacts with our immune system, the laureates contributed to the unprecedented rate of vaccine development during one of the greatest threats to human health in modern times,” the panel that awarded the prize said.

    Thomas Perlmann, secretary of the Nobel Assembly, announced the award and said both scientists were “overwhelmed” by news of the prize when he contacted them shortly before the announcement.

    The Nobel Prize in physiology or medicine was won last year by Swedish scientist Svante Paabo for discoveries in human evolution that unlocked secrets of Neanderthal DNA which provided key insights into our immune system, including our vulnerability to severe COVID-19.

    The award was the second in the family. Paabo’s father, Sune Bergstrom, won the Nobel Prize in medicine in 1982.

    Nobel announcements continue with the physics prize on Tuesday, chemistry on Wednesday and literature on Thursday. The Nobel Peace Prize will be announced Friday and the economics award on Oct. 9.

    The prizes carry a cash award of 11 million Swedish kronor ($1 million). The money comes from a bequest left by the prize’s creator, Swedish inventor Alfred Nobel, who died in 1896.

    The prize money was raised by 1 million kronor this year because of the plunging value of the Swedish currency.

    The laureates are invited to receive their awards at ceremonies on Dec. 10, the anniversary of Nobel’s death. The prestigious peace prize is handed out in Oslo, according to his wishes, while the other award ceremony is held in Stockholm.

    Corder reported from The Hague, Netherlands.

    Source link

  • 5 things to know about the new COVID-19 vaccine

    5 things to know about the new COVID-19 vaccine

    It may be time to get your COVID-19 vaccine again.

    There’s a new booster that’s coming out to guard against the virus. The Centers for Disease Control and Prevention said Tuesday that it was recommending the vaccine, which is being produced in versions by Moderna
    MRNA,
    +3.18%

    and Pfizer
    PFE,
    -0.20%

    -BioNTech
    BNTX,
    -2.06%
    ,
    for people 6 months of age and older.

    Here are answers to some common questions about the shot — and what you may need to know before you receive it.

    Why are we seeing another booster?

    Boosters are all about maintaining protection against the virus as new COVID-19 variants emerge. The CDC said: “The updated vaccines should work well against currently circulating variants of COVID-19, including BA.2.86, and continue to be the best way to protect yourself against severe disease.” The CDC also noted that “protection from COVID-19 vaccines and infection decline over time. An updated COVID-19 vaccine provides enhanced protection against the variants currently responsible for most hospitalizations in the United States.”

    So, everyone who is 6 months or older should receive it?

    That’s the CDC’s recommendation, but not everyone sees this booster as a firm requirement, depending on various medical and other factors.

    Dr. Paul A. Offit, a pediatrician with the Children’s Hospital of Philadelphia who specializes in infectious diseases, told MarketWatch that the new vaccine is a must for some who are at higher risk for developing serious illness, such as people who are over 75, people who have certain health problems (including diabetes, obesity or chronic lung or heart disease) and people who are immune compromised.

    And what about the others? Offit said it can be a case of “low risk, low reward.” Meaning there’s little harm in getting the booster and it may buy “a few months protection against mild disease,” Offit said. But he stops short of saying the booster is an absolute necessity for such people.

    Still, CDC director Dr. Mandy K. Cohen counters such an argument. In a column for the New York Times, Cohen noted that all the members of her family, including her 9- and 11-year-old daughters, would be getting the booster. “Some viruses…change over time. This coronavirus is one of them. It finds ways to evade our immune systems by constantly evolving. That’s why our vaccines need to be updated to match the changed virus,” Cohen explained.

    What if you recently had COVID? Or have just gotten the previous COVID booster?

    Offit said you should wait at least two months — and possibly as long as four months — before receiving the new vaccine.

    The CDC said, “You should get a COVID-19 vaccine even if you already had COVID-19,” adding “you may consider delaying your next vaccine by 3 months from when your [COVID] symptoms started or, if you had no symptoms, when you received a positive test.”

    When and where can you get the new booster?

    The CDC said the vaccine “will be available by the end of this week at most places you would normally go to get your vaccines.”

    How much will it cost?

    The new shots are expected to have list prices of $110 to $130, but the CDC said, “Most Americans can still get a COVID-19 vaccine for free.” That is, most health-insurance plans will cover the cost.

    As for those without insurance, the CDC said there are still plenty of free options, including programs run by local health centers and health departments as well as pharmacies participating in the CDC’s Bridge Access Program. For more information about where to get the booster, go to Vaccines.gov.

    Source link

  • CDC recommends updated COVID shots for people 6 months of age and older

    CDC recommends updated COVID shots for people 6 months of age and older

    The Centers for Disease Control and Prevention on Tuesday recommended updated COVID-19 vaccines for people 6 months of age and older.

    Director Mandy Cohen late Tuesday backed the findings of CDC advisers, who voted 13-to-1 for approval earlier in the day. The updated vaccines from Moderna Inc.
    MRNA,
    -0.53%

    and Pfizer Inc.
    PFE,
    +0.62%

    -BioNTech
    BNTX,
    -1.97%

    should become available later this week.

    “We have more tools than ever to prevent the worst outcomes from COVID-19,” Cohen said in a statement. “CDC is now recommending updated COVID-19 vaccination for everyone 6 months and older to better protect you and your loved ones.”

    The move comes just one day after the U.S. Food and Drug Administration approved the updated shots from Moderna and Pfizer. The FDA approved single-dose vaccines for people 12 and older and authorized emergency use of new shots for children as young as 6 months.

    The CDC recommendations Tuesday include some key changes from the recommendations that previously applied to the bivalent COVID vaccines. People age 65 and older were recommended to get a second bivalent dose, for example, but the CDC is not currently recommending two doses of the new shot for older adults. The CDC said it will monitor epidemiology and vaccine effectiveness to determine if additional doses are needed.

    The recommendations come as the vaccines are transitioning from federal procurement and distribution to the commercial market. The new shots are expected to have list prices of $110 to $130 per dose. But the Affordable Care Act requires insurers to cover most vaccines recommended by the CDC advisory committee at no cost to plan enrollees, and people with Medicare and Medicaid also have no-cost access to the vaccines. 

    The CDC meeting Tuesday addressed some concerns about the accessibility and cost of the vaccines for people without health-insurance coverage. The CDC’s new Bridge Access program will provide free shots to uninsured people within days at retail pharmacies as well as local health centers, the CDC said. The agency had previously said that the free shots might not arrive in retail pharmacies until mid-October. The federal government’s vaccines.gov website will be updated later this week to list Bridge Access program sites, the CDC said.

    Roughly 25 million to 30 million U.S. adults do not have health insurance. About 85% of people without coverage live within 5 miles of a Bridge Access program site, according to CDC data.

    Under the Bridge Access program, CVS Health Corp.
    CVS,
    +2.57%

    will administer doses in stores and Minute Clinics, the CDC said, and Walgreens Boots Alliance Inc.
    WBA,
    +1.35%

    will offer doses in stores and at off-site events that target areas of low access and uptake. Healthcare-services company eTrueNorth is also working with the program to reach lower-access areas without other coverage under the program, the CDC said.

    Source link

  • New coronavirus variant has experts on alert and WHO is urging countries to step up COVID surveillance

    New coronavirus variant has experts on alert and WHO is urging countries to step up COVID surveillance

    A new variant of the SARS-CoV-2 coronavirus has put epidemiologists around the world on alert, and the World Health Organization is asking countries to sustain early warning, surveillance and reporting systems as it works to evaluate the current COVID-19 risk level.

    The BA.2.86 variant, which was first detected in Israel, was designated a new variant under monitoring by the WHO on Aug. 17, after the agency received nine sequences from five countries — three in the WHO’s European Region, one in the African Region and one in the Region of the Americas.

    The variant has more than 30 mutations in the spike protein compared with the XBB variants that are currently dominant in the U.S. and around the world, namely XBB.1.16 and EG.5, which has been dubbed Eris, following the Greek-alphabet designation used for other variants.

    The WHO made EG.5 a variant of interest, or VOI, earlier this month, which is an upgrade from the designation of variant under monitoring, or VUM.

    But BA.2.86 is worrying experts because there is too little data to assess its potential impact.

    “It is crucial to sustain early warning, surveillance and reporting, variant
    tracking, early clinical care provision, administration of vaccine boosters to high-risk groups, improvements in ventilation, and regular communication,” the agency said in its latest weekly update.

    That update, which reviews the state of the virus for the 28-day period through Aug. 20, contains no data from the WHO’s Region of the Americas, as reports for the period were incomplete. That’s a worry that the WHO has consistently warned about as countries pull back on their monitoring of the illness as they seek to put the pandemic behind them.

    The WHO officially declared the emergency phase of the pandemic to be over on May 5 but emphasized that COVID remains a major threat. Many countries have dismantled much of their systems of oversight and greatly reduced testing and data measurement.

    See also: New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    The U.S. Centers for Disease Control and Prevention offered an update this week on BA.2.86 — which it said has been detected in Denmark, South Africa, Israel, the U.S. and the U.K. — and said the multiple locations are a sign of international transmission. The CDC acknowledged the surveillance challenge.

    “Notably, the amount of genomic sequencing of SARS-CoV-2 globally has declined substantially from previous years, meaning more variants may emerge and spread undetected for longer periods of time,” the U.S. agency said in its update.

    The CDC also noted a current increase in hospitalizations in the U.S., although it said that’s not likely driven by the BA.2.86 variant.

    “It is too soon to know whether this variant might cause more severe illness compared with previous variants,” said the CDC.

    Perhaps the bigger issue is whether the new variant has greater escape from existing immunity from vaccines and previous infections, compared with other recent variants.

    “One analysis of mutations suggests the difference may be as large as or greater than that between BA.2 and XBB.1.5, which circulated nearly a year apart,” the CDC said. “However, virus samples are not yet broadly available for more reliable laboratory testing of antibodies, and it is too soon to know the real-world impacts on immunity.”

    Americans gearing up for what’s expected to be an annual COVID vaccine booster this fall can be confident those vaccines will be designed to protect against all subvariants of XBB, including Eris, the agency said.

    The CDC said it’s likely that antibodies built up in the population through infection, vaccination or both will provide protection against BA.2.86. However, it said, “this is an area of ongoing scientific investigation.”

    Eric Topol, the chair of innovative medicine at Scripps Research in La Jolla, Calif., said the ability to neutralize the virus depends on the levels of neutralizing antibodies, and those are bound to be lower against BA.2.86 than earlier variants that people have been exposed to or immunized against.

    “Also to note, the burden of new mutations for BA.2.86 is not confined to the spike and is seen broadly across other components of the virus,” he wrote in commentary this week. “If BA.2.86 takes off, it will be a real test of how good our T-cell response can rev up to meet the challenge.”

    Meanwhile, the CDC’s weekly projections for where Eris and other variants are circulating continue to be hampered by a shortage of data. In early August, the CDC said it would unable to  publish its “Nowcast” projections because it did not have enough sequences to update the estimates.

    “Because Nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley told MarketWatch at the time.

    The agency had received data from just three U.S. regions. In its most recent weekly update for the week through Aug. 19, it also got data from just three regions.

    Separately, the CDC reported a 21.6% increase in U.S. hospitalizations for COVID in the week through Aug. 12. Deaths rose 21.4% in the week through Aug. 19.

    Source link

  • WHO names Eris a COVID variant of interest. Here’s what you need to know.

    WHO names Eris a COVID variant of interest. Here’s what you need to know.

    The World Health Organization has upgraded COVID-19 variant EG.5 to a variant of interest, or VOI, from a variant under monitoring, or VUM, as it continues to become more prevalent around the world.

    The variant — which has been nicknamed Eris by some media, following the Greek-alphabet designation used for other variants — has been found in 51 countries, with most sequences, 30.6%, stemming from China, said the WHO.

    Other countries that have submitted at least 100 sequences to a central database include the U.S., the Republic of Korea, Japan, Canada, Australia, Singapore, the United Kingdom, France, Portugal and Spain, the WHO said in a statement.

    Eris is a descendent lineage of XBB.1.9.2, which is an omicron subvariant. It was first detected on Feb. 17 and designated as a VUM on July 19.

    Its latest designation means it’s more prevalent than it was, has a growth advantage over earlier variants and merits closer monitoring and tracking.

    Here’s what you need to know about Eris.

    Eris is spreading around the world

    The strain is increasing in global prevalence, accounting for 17.4% of cases sequenced in the week through July 23, up from 7.6% four weeks earlier. The WHO has been tracking COVID data on a 28-day basis, largely because countries have cut back on testing and surveillance as they emerge from the pandemic, meaning the agency has far less data than it did during the pandemic.

    It’s already dominant in the U.S.

    Eris has become dominant in the U.S., according to projections made by the Centers for Disease Control and Prevention, although a shortage of data is hampering the agency’s efforts to surveil the illness.

    The CDC said last week it was unable to publish its “nowcast” projections, which it releases every two weeks, for where EG.5 and other variants are circulating for every region, because it did not have enough sequences to update the estimates.

    “Because nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley told MarketWatch.

    “For some regions, we have limited numbers of sequences available and therefore are not displaying nowcast estimates in those regions, though those regions are still being used in the aggregated national nowcast,” she said.

    It is estimated that EG.5, an omicron subvariant, accounted for 17.3% of COVID cases in the U.S. in the two-week period through Aug. 5. That was up from an estimated 11.9% in the previous period and was more than any other variant.

    For more, see: New Eris COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    It’s no riskier than earlier variants

    The public-health risk is deemed to be low at the global level, lining up with the risk posed by XBB.1.16 and other currently circulating VOIs, according to the WHO statement. But it’s likely more infectious.

    “While EG.5 has shown increased prevalence, growth advantage, and immune escape properties, there have been no reported changes in disease severity to date,” said the WHO.

    That growth advantage and immune-escape properties mean Eris may cause a rise in case incidence over time and become dominant in some countries or even the world, according to the WHO.

    It has the same symptoms as other strains

    The Eris variant causes the same symptoms as seen with other strains of COVID, such as sore throat, runny nose, cough, congestion, fever, fatigue, body aches and a possible loss of taste or smell.

    The best defense against Eris is vaccination

    Like earlier strains of COVID, the best protection is to be vaccinated with any of the vaccines developed by Pfizer Inc.
    PFE,
    -0.03%

    and German partner BioNTech SE
    BNTX,
    -0.32%
    ,
    Moderna Inc.
    MRNA,
    -1.01%

    or Novavax Inc.
    NVAX,
    +9.83%

    The vaccines that will be made available in the fall will be designed to protect against all subvariants of XBB, including Eris.

    Source link

  • New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    New ‘Eris’ COVID variant is dominant in the U.S., but a shortage of data is making it hard to track

    A new variant of COVID-19 dubbed EG.5 has become dominant in the U.S., according to projections made by the Centers for Disease Control and Prevention, although a shortage of data is hampering the agency’s efforts to surveil the illness.

    The CDC said on Friday it was unable to publish its “Nowcast” projections for where EG.5 and other variants are circulating for every region, which it releases every two weeks, because it did not have enough sequences to update the estimates.

    “Because Nowcast is modeled data, we need a certain number of sequences to accurately predict proportions in the present,” CDC representative Kathleen Conley said in a statement to CBS News.

    “For some regions, we have limited numbers of sequences available, and therefore are not displaying nowcast estimates in those regions, though those regions are still being used in the aggregated national nowcast.”

    It is estimated that EG.5, an omicron subvariant, accounted for 17.3% of COVID cases in the U.S. in the two-week period through Aug. 5. That was up from an estimated 11.9% in the previous period and more than any other variant.

    But the data are based on sequencing from just three regions; Region 2, comprising New Jersey, New York, Puerto Rico and the U.S. Virgin Islands; Region 4, comprising Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina and Tennessee; and Region 9, comprising Arizona, California, Hawaii, Nevada, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Marshall Islands and Republic of Palau.

    The next most common variants are XBB.1.16, accounting for 15.6% of cases, and XBB.2.3, accounting for 11.2% of cases.

    All are subvariants of XBB, which COVID vaccines in the fall will be designed to protect against.

    The symptoms of EG.5, which Twitter users have nicknamed “Eris,” are similar to early variants, and it’s not deemed to be more virulent than early variants. It may be more infectious, however, as has been the pattern with new strains. Symptoms include a cough, fever, chills, shortness of breath, fatigue and a loss of taste or smell.

    The World Health Organization said last week that EG.5 increased in prevalence globally to 11.6% in the week through July 30 from 62% four weeks earlier.

    The variant is for now a variant under monitoring, or VUM, for the agency, which is a less serious designation than a variant of interest, or VOI, according to its weekly epidemiological update.

    The WHO is monitoring two VOIs, XBB.1.5 and XBB.1.6.

    It is tracking seven VUMs and their descendent lineages, namely BA.2.75, CH.1.1, XBB, XBB.1.9.1, XBB.1.9.2, XBB.2.3 and EG.5.

    CDC data show that hospital admissions with COVID started to rise again in July after being flat or falling for several months. But the number of deaths continues to decline with 81.4% of the overall population in the U.S. having had at least one vaccine dose.

    Source link

  • COVID pandemic is officially over in the U.S., excess-deaths data show

    COVID pandemic is officially over in the U.S., excess-deaths data show

    The COVID-19 pandemic is definitively over, according to two recent reports focused on the same metric.

    That metric is excess deaths, a measure of the difference between the number of deaths that occurred through the pandemic years, beginning in March 2020, and the number that would be expected in a nonpandemic year, based on data from earlier years.

    At…

    Source link

  • U.S. dollar could soon wipe out all of its post-pandemic gains, Soc Gen strategist warns

    U.S. dollar could soon wipe out all of its post-pandemic gains, Soc Gen strategist warns

    The slide in the U.S. dollar in the last eight months could mean that mean all of its gains in the wake of the coronavirus pandemic will soon be lost, according to Kit Juckes, a macro strategist at Société Générale who has been a long-time currency analyst.

    Juckes said in a note shared with SocGen clients and the media on Tuesday that he expects the greenback could return to its lows from December 2020, the level it fell to during the pandemic given the market is pricing in an end to interest rate rises by the Federal Reserve this year.

    “As was the case in January/February before the SVB mini crisis, the market is anticipating the peak in US rates and a further narrowing relative rates. If nothing happens to scupper those expectations (another upside surprise in US growth, or further European growth disappointment) I would expect the Dollar Index to move closer but not all the way to, the lows at the end of 2020,” he said.

    “That won’t happen in a straight line and will require further interest rate convergence between the U.S. and other major economies, however.”

    Over the past week, investors’ expectations about the outlook for where U.S. interest rates are headed have shifted. Following lower-than-expected readings last week on U.S. June inflation, as measured by the consumer price index and the producer price index, many investors expect the Fed will raise its benchmark interest rate only once more when the central bank holds its policy meeting next week.

    Read this next: U.S. stocks benefiting from ‘sense of urgency’ as investors rush into equity mutual funds

    Fed-funds futures, which are used to bet on the expected path of interest rates, are pricing in nearly a 100% probability of a hike in July, but analysts also think rate cuts could come by the Fed’s January policy meeting, where futures markets already see a nearly 40% probability of a cut, according to CME’s FedWatch tool.

    This shift in expectations has triggered a wave of dollar-bearishness across Wall Street, with many top currency analysts opining that the path of least resistance for the U.S. dollar is likely lower.

    The ICE U.S. Dollar Index
    DXY,
    +0.13%
    ,
    a gauge of the dollar’s strength against a basket of major currencies, was trading modestly higher on Tuesday, up 0.1% at 99.96, but on Monday, the index touched its lowest level since mid-April 2022.

    Back in December 2020, it briefly broke below 90 to what was at the time its weakest level in more than two years.

    Read more: Why stocks could get a boost from a falling U.S. dollar

    Another important question for markets will be whether the dollar’s peak in late September 2022, when the dollar index traded just shy of 115, its highest level in more than two decades, will mark a long-term cyclical peak. As Juckes notes, the dollar has traded at a succession of higher lows since 2007.

    Another issue on Juckes’ radar: the prospect that the U.S. dollar and Chinese yuan
    USDCNY,
    +0.35%

    could weaken in tandem. Juckes said he expects the yuan to climb to 7.40 against the dollar by the end of the year, a level it hasn’t seen in roughly 15 years.

    The onshore renminbi, which incorporates the yuan’s more tightly controlled exchange rate within China, was trading at 7.18, with the dollar climbing 0.1%.

    While American consumers could see the price of imported goods rise and international travel become more expensive, a weaker dollar could also help boost U.S. equity prices, as earnings of exporters get a boost from the currency’s slide, and the chances of a global recession eases, as MarketWatch reported on Monday.

    Source link

  • World Health Organization declares end to COVID global health emergency

    World Health Organization declares end to COVID global health emergency

    The World Health Organization on Friday declared an end to the COVID-19 global health emergency.

    Speaking at a press conference at the agency’s headquarters in Geneva, WHO Director-General Dr. Tedros Adhanom Ghebreyesus said he had accepted the advice of an expert committee, which met on Thursday, regarding the pandemic’s status. “It is therefore with great hope that I declare COVID-19 over as a global health emergency,” he said.

    The…

    Source link

  • The doctor won’t Zoom with you now: The telehealth frenzy is over.

    The doctor won’t Zoom with you now: The telehealth frenzy is over.

    The pandemic opened the floodgates to telehealth. Now, many patients and doctors are curbing their enthusiasm for virtual care. 

    Four out of five primary-care doctors who had video visits with patients during the pandemic would prefer to provide just a small portion of care or no care at all via telemedicine in the future, according to a survey designed and analyzed by researchers at Harvard T.H. Chan School of Public Health and published last month in Health Affairs, a peer-reviewed journal. And 60% of the doctors surveyed…

    Source link

  • Loneliness is an ‘epidemic’ that costs billions and leads to bad health outcomes and even death

    Loneliness is an ‘epidemic’ that costs billions and leads to bad health outcomes and even death

    Loneliness is more than a bad feeling. It’s as deadly as smoking up to 15 cigarettes a day and is associated with a greater risk of cardiovascular disease, dementia, stroke, depression, anxiety, and premature death, according to an advisory by the U.S. Surgeon General.

    The mortality impact of being socially disconnected is greater than that of obesity and physical inactivity, U.S. Surgeon General Vivek Murthy said in an 81-page report called “Our Epidemic of Loneliness and Isolation.”

    Social isolation among older adults alone accounts for about $6.7 billion in excess Medicare spending a year, largely due to increased hospital and nursing facility spending, the report said. 

    Read: Depression, isolation, loss of purpose: Could retirement be bad for your mental health?

    Loneliness and isolation also are connected with lower academic achievement and worse performance at work. In the U.S., stress-related absenteeism attributed to loneliness costs employers an estimated $154 billion annually, according to the report.

    “Given the profound consequences of loneliness and isolation, we have an opportunity, and an obligation, to make the same investments in addressing social connection that we have made in addressing tobacco use, obesity, and the addiction crisis,” the report said. Still, no federal funding or programming will be provided to combat the issue.

    Essentially, social connection is a significant predictor of longevity and better physical, cognitive, and mental health, while social isolation and loneliness are significant predictors of premature death and poor health, the report said.

    Read: Americans are lonelier than ever—and that’s bad for your health

    The Surgeon General’s advisory is intended as a public statement that calls the people’s attention to an urgent public health issue and provides recommendations for how it should be addressed. Advisories are reserved for significant public health challenges that require the nation’s immediate awareness and action, the report said.

    “Each of us can start now, in our own lives, by strengthening our connections and relationships. Our individual relationships are an untapped resource—a source of healing hiding in plain sight. They can help us live healthier, more productive, and more fulfilled lives,” the report said. “Answer that phone call from a friend. Make time to share a meal. Listen without the distraction of your phone. Perform an act of service. Express yourself authentically. The keys to human connection are simple, but extraordinarily powerful.”

    Americans have become less connected to houses of worship, community organizations and their own families and have reported an increase in feelings of loneliness. The number of single households has also doubled over the last 60 years.

    About half of U.S. adults report experiencing loneliness, with some of the highest rates among young adults. People cut their circles of friends during the Covid-19 pandemic and reduced time spent with those friends, according to the report. 

    Read: ‘When we retire, we lose a lot.’ How to avoid retirement shock.

    Americans spent about 20 minutes a day in person with friends in 2020, down from 60 minutes daily nearly two decades earlier. Among young people, ages 15 to 24, time spent in-person with friends has reduced by nearly 70% over almost two decades, from roughly 150 minutes per day in 2003 to 40 minutes per day in 2020, the report said. 

    Technology has made loneliness worse. People who used social media for two hours or more daily were more than twice as likely to report feeling socially isolated than those who used such technology for less than 30 minutes a day, according to the report.

    Murthy called on technology companies, employers, community-based organizations, parents and individuals to tackle the problem. 

    “We are called to build a movement to mend the social fabric of our nation. It will take all of us…working together to destigmatize loneliness and change our cultural and policy response to it.

    It will require reimagining the structures, policies, and programs that shape a community to best support the development of healthy relationships,” Murthy said. 

    Source link

  • China is not only asserting itself geopolitically but openly questioning the U.S.’s central role on the world stage

    China is not only asserting itself geopolitically but openly questioning the U.S.’s central role on the world stage

    It’s been a busy few months for China — and sobering ones for the United States.

    Days later, Beijing announced it had brokered a deal that will see Persian Gulf rivals Saudi Arabia and Iran normalize relations, a shocking diplomatic coup in an area long dominated by the United States. Xi was reportedly personally involved in the negotiations.

    “This landmark agreement has the potential to transform the Middle East by realigning its major powers,” the journal Foreign Affairs declared, adding that the gambit is “weaving the region into China’s global ambitions. For Beijing, the announcement was a great leap forward in its rivalry with Washington.”

    But the biggest news came two weeks ago, when Xi flew to Moscow and met with Vladimir Putin, just days after the International Criminal Court in the Hague issued an arrest warrant for the Russian president on charges of war crimes in Russia’s year-old invasion of Ukraine.

    ‘China has seen a space where it is hard for the West to really block off — heading into issues [that the Western powers] feel are too intractable or too toxic to touch and trying to demonstrate that there might be a different way to mediate or involve yourself in these problems.’


    — Kerry Brown, King’s College London

    “There are changes coming that haven’t happened in 100 years,” Xi told Putin as the self-described “dear friends” concluded their talks. “When we are together, we are driving these changes.”

    China’s assertiveness comes after three years of COVID restrictions that saw the country close off from the world in an attempt to tame the virus, a policy that was suddenly scrapped in December.

    “It has sunk in that China needs friends. It has ended up too isolated, and that has cut across the narrative of the Xi third term, which was due to be somewhat more sunny,” Kerry Brown, director of the Lau China Institute at King’s College London, told MarketWatch.

    Others agreed. “China certainly is exiting a period of diplomatic isolation during the height of COVID,” said Victor Shih, the Ho Miu Lam chair in China and Pacific relations at the University of California, San Diego, and an expert on Chinese elite politics.

    That exit has been swift, with Beijing taking concrete steps toward a belief that previously had been mostly rhetoric — that the U.S.-led global system is not the only path.

    “China has seen a space where it is hard for the West to really block off — heading into issues [that the Western powers] feel are too intractable or too toxic to touch and trying to demonstrate that there might be a different way to mediate or involve yourself in these problems,” Brown said.

    Those sentiments are increasingly pervasive across China, particularly in government, academia and media.

    “The U.S., which is accustomed to enjoying the spotlight, is now puzzled for it never thought that one day China would be more popular than it,” state tabloid Global Times said in a front-page story last Thursday.

    Wang Yong, director of the Center for International Political Economy and the Center for American Studies at Peking University, told MarketWatch, “The rise of China as a great power is facing an increasingly complicated situation, mainly because U.S. elites judge China as the foremost strategic and systemic threat, and attack China’s development.”

    Wang highlighted concerns over Washington’s policy toward self-ruled Taiwan, which Beijing claims as a renegade province.

    In fact, Taiwanese President Tsai Ing-wen is stopping over in the U.S. this week after visits to the island’s few remaining allies in Central America. Beijing has threatened for weeks against her being welcomed by any high-level American officials.

    Those threats turned to ire on Monday, when Republican House Speaker Kevin McCarthy said he would meet with Tsai on Wednesday in California. China said this could lead to “serious confrontation” and that Beijing would “resolutely fight back” — without giving specifics.

    ‘Why is it assumed we live in a U.S. world?’


    — Alan Ma, graduate student, Tsinghua University.

    “Gradually deviating from the past promise of ‘one China,’ promoting Taiwan independence and using Taiwan to contain China’s development — these could trigger a China-U.S. war,” Peking University’s Wang said from Beijing.

    See: U.S. tells China not to ‘overreact’ to Taiwan leader’s stopover

    Average citizens including younger people expressed frustration with U.S. policy.

    Taiwan’s president, Tsai Ing-wen, arrives on Thursday at her hotel in New York.


    AP/John Minchillo

    “Why isn’t it China’s time to lead? Why is it assumed we live in a U.S. world?” asked 27-year-old Alan Ma, a graduate student in politics at Beijing’s Tsinghua University.

    Other areas are reaching heightened levels of tension. China’s military said last month it drove out an American destroyer ship that had “illegally” entered the South China Sea. And the CEO of Chinese-owned video sensation TikTok appeared before U.S. lawmakers in hopes of preventing an American ban on the app over national-security concerns.

    Context: Biden White House and bipartisan group of 12 senators back TikTok ban

    Also: TikTok is the next Chinese product the U.S. could shoot down

    But China’s rise, however rapid, must be put in a realistic context, experts said.

    “I don’t think that we can say China has entered a new period as a global power until it has deployed large troop contingents overseas on its own,” said UC San Diego’s Shih.

    Tanner Brown covers China for MarketWatch and Barron’s.

    Source link

  • Leading infectious-disease expert says COVID-19 is now endemic, but Americans are divided on whether pandemic is over

    Leading infectious-disease expert says COVID-19 is now endemic, but Americans are divided on whether pandemic is over

    A leading infectious-disease expert said this week that data is showing the coronavirus has moved to the endemic phase, meaning that COVID-19 is still with us but no longer causing huge waves of illness or clogging up healthcare systems.

    Eric Topol, the chair of innovative medicine at Scripps Research in La Jolla, Calif., said all indications from genomic surveillance of the virus, wastewater and clinical outcomes that are still being tracked point to an endemic phase. The caveat is that monitoring is more limited now and tracking is happening at lower frequency.

    Nonetheless, “there are no new SARS-CoV-2 variants that have yet cropped up with a growth advantage over XBB.1.5 (the recombinant with two significant mutations added on), which is dominant throughout much of the world, or its cousin, XBB.1.91.1,” Topol wrote in his Ground Truths Substack column.

    “For all the talk about the convergent ‘variant soup’ that preceded the most recent wave, the XBBs took hold and are not giving way to a long list of omicron family sub-variants,” he added.

    The New York Times daily tracker shows that cases are now averaging around 29,558 a day, down 15% from two weeks ago and at a level last seen around April 2022.

    Hospitalizations are down 11% at 24,965 a day. But the daily average death toll stands at 401, up 21% from two weeks ago and an undesirably high number.

    The Johns Hopkins University global tracker will stop collecting data on Saturday, which marks the third anniversary of the World Health Organization’s declaration of a global state of emergency.

    The tracker shows there have been 676.6 million cases of COVID and 6.8 million deaths globally since the start of the crisis. The U.S. leads the world with 103.8 million cases and 1.12 million deaths.

    The WHO counted nearly 4.5 million new COVID cases globally in the 28-day period through March 5, down 58% from the previous period, according to its weekly epidemiological update. The agency said some 32,000 deaths were reported, down 65% from the previous 28-day period.

    As has become its practice, it cautioned that an overall pullback in testing means those numbers are likely an undercount as prevalence surveys show higher ones.

    The WHO is now monitoring one variant of concern, namely omicron, and seven of its subvariants. The following table shows the weekly prevalence of those subvariants over time:


    World Health Organization

    A new Gallup poll, meanwhile, shows Americans are evenly divided over whether or not the pandemic is over: Some 49% say it is, while 51% say it’s not.

    Gallup first started asking the American public its views on the topic in June 2021, a time when many states were lifting restrictions on movement as the vaccine rollout was underway. At the time, just 29% of those polled said they thought the pandemic was over, giving way to a less upbeat 18% by fall of that year.

    “Since then, optimism has mostly only inched higher, rising to 34% last spring and to 44% in October before reaching 49% today,” said Gallup.

    A quarter of those polled said they are very or somewhat worried about contracting COVID. That was split between 3% who are very worried and 22% who are somewhat worried. Concerns spiked at 50% in January 2022, when omicron first started to circulate.

    The Gallup survey also found that many Americans are still at least partially isolating to protect themselves from the virus. Some 23% of those polled said they are still avoiding crowds, 18% are avoiding travel by air or public transportation and 14% are avoiding public places such as stores and restaurants. Just 10% are even avoiding small gatherings.

    But most people are no longer wearing face masks, with just 31% saying they still use one.


    Gallup

    A small majority of those surveyed, or 52%, said they have tested positive for COVID. Another 13% said they had not, but believed they have had the virus.

    As many as 83% of Americans may have some immunity against the virus due to the higher number that have had it and the 63% who are vaccinated, the survey found.

    Source link

  • Alibaba Stock Jumps After Earnings Beat. Chinese Lockdowns Still Weighed.

    Alibaba Stock Jumps After Earnings Beat. Chinese Lockdowns Still Weighed.



    Alibaba


    reported better-than-expected earnings in the final three months of 2022, giving Wall Street exactly what it wanted as analysts remain positive on the Chinese tech giant. 

    But there are signs that the destructive Covid-19 lockdowns that hurt the world’s second-largest economy last year continue to linger.

    Source link

  • Omicron subvariant that’s dominant in U.S. extends lead over other variants in latest week, CDC data shows

    Omicron subvariant that’s dominant in U.S. extends lead over other variants in latest week, CDC data shows

    The omicron subvariant that became dominant in the U.S. several weeks ago continued to extend its lead over other variants in the latest week, according to Centers for Disease Control and Prevention data that was updated on Friday.

    XBB.1.5, the omicron sublineage that first emerged in small numbers in October, accounted for 66.4% of cases in the week through Feb. 4, the data shows. That’s up from 61.3% the previous week. The prior dominant variants, BQ.1.1 and BQ.1, together accounted for 27.2% of new cases, down from 31.1% the previous week.

    In the CDC’s Region 2, which includes New York, New Jersey, the U.S. Virgin Islands and Puerto Rico, XBB.1.5 accounted for 92.4% of new cases, up from 91.1% the previous week.

    The World Health Organization is monitoring XBB and its sublineages and has said that so far, it shows a growth advantage over other circulating variants — in other words, it’s more infectious — but there is still no data to suggest it’s any more lethal, or likely to cause severe illness or death.

    The WHO said this week the pandemic is not yet over, although the world may be reaching an inflection point as higher immunity rates lower death rates. But it also urged countries to stay the course, while President Joe Biden has pledged to end twin COVID emergencies on May 11, a move that has dismayed healthcare experts.

    Travel between Hong Kong and China will no longer require COVID-19 PCR tests nor be held to a daily limit, authorities announced Friday, as both places seek to drive economic growth, the Associated Press reported.

    Hong Kong’s tourism industry has suffered since 2019 after months of political strife that at times turned into violent clashes between protesters and police, as well as harsh entry restrictions implemented during the pandemic.

    The announcement came a day after Lee unveiled a tourism campaign aimed at attracting travelers to Hong Kong that includes 500,000 free air tickets for tourists to visit the semi-autonomous Chinese city.

    Read also: What happens when the COVID-19 emergency declaration ends? Brace for big changes to your health coverage and medical costs

    In the U.S., the seven-day average of new U.S. COVID cases stood at 41,412 on Thursday, according to a New York Times tracker. That’s down 19% from two weeks ago. The daily average for hospitalizations was down 21% at 31,394. The average for deaths was 462, down 7% from two weeks ago.

    Cases are now rising in 17 states, the tracker shows, led by Minnesota, where they are up 63% from two weeks ago. On a per capita basis, cases are highest in Kentucky at 22 per 100,000 residents.

    Coronavirus update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • China’s COVID lockdowns, and the ending of them in December that sparked a wave of cases, are featuring prominently in U.S. fourth-quarter earnings, with Starbucks
    SBUX,
    -2.68%

    the latest company to highlight their impact on its performance. The coffee-shop chain’s stock was down 3.8% Friday, after it said same-store sales in China, a key market, fell 29% because of the case surge. That was enough to drag down international same-store sales, which had an overall drop of 13%. Still, Chief Financial Officer Rachel Ruggeri said on the call that, “excluding China, we had tremendous growth across markets.” She also said the company’s fiscal 2023 outlook remains unchanged.

    • Some Georgia senators want to permanently block schools and most state and local government agencies from requiring people to get vaccinated against COVID, the AP reported. In 2022, lawmakers put a one-year ban into law, part of a nationwide conservative backlash against mandates meant to prevent the spread of the respiratory illness. But that ban expires on June 30 in Georgia if lawmakers don’t act. The Senate Health and Human Services Committee voted 7-2 this week to advance Senate Bill 1, which makes the ban permanent, to the full Senate.

    • After a two-year hiatus due to the coronavirus pandemic that brutally brought one of Europe’s oldest Mardi Gras celebrations in Binche, Belgium to a halt, celebrations are back with a vengeance this winter, the AP reported. The earliest records of the Binche Mardi Gras, which draws thousands of revelers, date to the 14th century. Many Belgian towns hold ebullient carnival processions before Lent. But what makes Binche unique are the “Gilles”—local men deemed fit to wear the Mardi Gras costumes. Under rules established by the local folklore defense association, only men from Binche families or having resided there for at least five years are eligible to wear the Gille costume. Other characters—the Peasant, the Sailor, the Harlequin, the Pierrot or the Gille’s Wife—also play a role in the carnival.

    Here’s what the numbers say:

    The global tally of confirmed COVID-19 cases topped 671.3 million on Monday, while the death toll rose above 6.83 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 102.5 million cases and 1,110,856 fatalities.

    The CDC’s tracker shows that 229.6 million people living in the U.S., equal to 69.2% of the total population, are fully vaccinated, meaning they have had their primary shots.

    So far, just 51.4 million Americans, equal to 15.5% of the overall population, have had the updated COVID booster that targets both the original virus and the omicron variants.

    Source link

  • WHO counted nearly 20 million new COVID cases in latest month as it shifts from weekly reporting schedule

    WHO counted nearly 20 million new COVID cases in latest month as it shifts from weekly reporting schedule

    The World Health Organization said nearly 20 million new COVID cases were recorded in the 28 days through Jan. 29, down 78% from the previous 28 days.

    The WHO counted more than 114,000 deaths in the period, up 65% from the previous one.

    The agency is switching to a 28-day interval to smooth out weekly fluctuations in cases and deaths, but it continues to caution that a reduction in testing and delays in reporting in many countries are distorting the numbers.

    “Current trends in reported COVID-19 cases are underestimates of the true number of global infections and reinfections as shown by prevalence surveys,” the WHO said in its weekly epidemiological update. 

    The WHO is now prioritizing four omicron descendent lineages, including XBB.1.5, which is dominant in the U.S., according to data from the Centers for Disease Control and Prevention.

    The other three are BF.7, BQ.1 and BA.2.75, along with their sublineages. These are currently the ones showing a growth-rate advantage in some countries compared with other circulating variants.

    U.S. cases are still declining. The seven-day average of new cases stood at 41,771 on Wednesday, according to a New York Times tracker. That’s down 23% from two weeks ago.

    The daily average for hospitalizations was down 22% at 31,593. The average for deaths was 453, down 6% from two weeks ago, but still an undesirably high number heading into the third year of the pandemic and ahead of President Joe Biden’s plan to end the twin COVID emergencies on May 11.

    Coronavirus update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Quest Diagnostics Inc.
    DGX,
    -1.55%

    is the latest healthcare company to report a steep drop in revenue from COVID-related products, in this instance a 74.6% slide in tests in its fourth quarter. Revenue from COVID tests fell to $184 million in the quarter from $722 million a year ago, when the omicron wave was about to crest. But the company still posted better-than-expected earnings, raised its quarterly dividend and added $1 billion to its share-buyback authorization, which has $311 million already available. 

    • Hong Kong will give away air tickets and vouchers to woo tourists back to the international financial hub as it races to catch up with other popular travel destinations in a fierce regional competition, the Associated Press reported. During the pandemic, the city largely aligned itself with mainland China’s zero-COVID strategy and has relaxed its entry rules months later than rival destinations such as SingaporeJapan and Taiwan. Even after it reopened its border with mainland China in January, tourism recovery was sluggish. On Thursday, Chief Executive John Lee launched a tourism campaign, “Hello Hong Kong,” saying the city will offer 500,000 free air tickets to welcome tourists from around the world in what he called “probably the world’s biggest welcome ever.”

    • Washington state Gov. Jay Inslee has tested positive for COVID-19 for the second time, the AP reported separately. Inslee’s office said in a statement Wednesday that he had tested positive and was experiencing very mild symptoms, including a cough. He is consulting with his doctor about whether to receive Paxlovid antiviral treatments, according to the statement. He plans to continue working. Trudi Inslee, his spouse, has tested negative.

    Here’s what the numbers say:

    The global tally of confirmed COVID-19 cases topped 671.1 million on Monday, while the death toll rose above 6.83 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 102.5 million cases and 1,109,687 fatalities.

    The CDC’s tracker shows that 229.6 million people living in the U.S., equal to 69.2% of the total population, are fully vaccinated, meaning they have had their primary shots.

    So far, just 51.4 million Americans, equal to 15.5% of the overall population, have had the updated COVID booster that targets both the original virus and the omicron variants.

    Source link